Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: The opioid growth factor (OGF) and its receptor (OGFr), serve as inhibitory axis regulating cell proliferation in normal cells and cancer. We investigated the presence and relative expression of OGF and OGFr in normal human ovarian surface epithelial (HOSE) cells, benign ovarian cysts, and ovarian cancers. Methods: Surgical samples of 16 patients with ovarian cancer and 27 patients with ovarian benign cysts were obtained intraoperatively. HOSE were collected by scraping the surface of normal ovaries of 10 post menopausal women undergoing hysterectomy and oophorectomy. Semiquantitative immunohistochemistry was used to assess the presence, distribution, and levels of OGF and OGFr. Receptor binding assays measured binding capacity and affinity of OGFr for radiolabeled OGF. Results: OGF and OGFr were present in HOSE cells, ovarian cysts, and ovarian cancers. Compared to HOSE cells, OGF and OGFr protein levels were reduced 29% and 34% (p < 0.001), respectively, in ovarian cysts, and decreased 58% and 48% (p < 0.001), respectively, in ovarian cancers. Binding assays revealed 5.4 fold fewer OGFr binding sites in cancers than cysts (p < 0.05). Levels of OGF and OGFr were comparable in primary, metastatic, or recurrent ovarian cancers. Conclusion: We have shown that a native opioid pathway, the OGF-OGFr axis, is present in human ovarian cancer. Importantly, the expression of OGF and OGFr is diminished in human ovarian cancer. As OGF and OGFr normally function in maintaining cell proliferation, therapy to harness OGF/OGFr function could provide a useful biologic-based treatment for human ovarian cancer.

Original languageEnglish (US)
Pages (from-to)319-324
Number of pages6
JournalGynecologic Oncology
Volume124
Issue number2
DOIs
StatePublished - Feb 1 2012

Fingerprint

Ovarian Neoplasms
Opioid Analgesics
Intercellular Signaling Peptides and Proteins
Ovarian Cysts
Epithelial Cells
methionine-enkephalin receptor
Cell Proliferation
Ovariectomy
Cell- and Tissue-Based Therapy
Biological Products
Hysterectomy
Cysts
Ovary
Neoplasms
Immunohistochemistry
Binding Sites

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology

Cite this

@article{cf5cd6981158432e8c56e597c5bb0af5,
title = "Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer",
abstract = "Objective: The opioid growth factor (OGF) and its receptor (OGFr), serve as inhibitory axis regulating cell proliferation in normal cells and cancer. We investigated the presence and relative expression of OGF and OGFr in normal human ovarian surface epithelial (HOSE) cells, benign ovarian cysts, and ovarian cancers. Methods: Surgical samples of 16 patients with ovarian cancer and 27 patients with ovarian benign cysts were obtained intraoperatively. HOSE were collected by scraping the surface of normal ovaries of 10 post menopausal women undergoing hysterectomy and oophorectomy. Semiquantitative immunohistochemistry was used to assess the presence, distribution, and levels of OGF and OGFr. Receptor binding assays measured binding capacity and affinity of OGFr for radiolabeled OGF. Results: OGF and OGFr were present in HOSE cells, ovarian cysts, and ovarian cancers. Compared to HOSE cells, OGF and OGFr protein levels were reduced 29{\%} and 34{\%} (p < 0.001), respectively, in ovarian cysts, and decreased 58{\%} and 48{\%} (p < 0.001), respectively, in ovarian cancers. Binding assays revealed 5.4 fold fewer OGFr binding sites in cancers than cysts (p < 0.05). Levels of OGF and OGFr were comparable in primary, metastatic, or recurrent ovarian cancers. Conclusion: We have shown that a native opioid pathway, the OGF-OGFr axis, is present in human ovarian cancer. Importantly, the expression of OGF and OGFr is diminished in human ovarian cancer. As OGF and OGFr normally function in maintaining cell proliferation, therapy to harness OGF/OGFr function could provide a useful biologic-based treatment for human ovarian cancer.",
author = "James Fanning and Hossler, {Carrie A.} and Kesterson, {Joshua P.} and Donahue, {Renee N.} and McLaughlin, {Patricia J.} and Zagon, {Ian S.}",
year = "2012",
month = "2",
day = "1",
doi = "10.1016/j.ygyno.2011.10.024",
language = "English (US)",
volume = "124",
pages = "319--324",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer. / Fanning, James; Hossler, Carrie A.; Kesterson, Joshua P.; Donahue, Renee N.; McLaughlin, Patricia J.; Zagon, Ian S.

In: Gynecologic Oncology, Vol. 124, No. 2, 01.02.2012, p. 319-324.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer

AU - Fanning, James

AU - Hossler, Carrie A.

AU - Kesterson, Joshua P.

AU - Donahue, Renee N.

AU - McLaughlin, Patricia J.

AU - Zagon, Ian S.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Objective: The opioid growth factor (OGF) and its receptor (OGFr), serve as inhibitory axis regulating cell proliferation in normal cells and cancer. We investigated the presence and relative expression of OGF and OGFr in normal human ovarian surface epithelial (HOSE) cells, benign ovarian cysts, and ovarian cancers. Methods: Surgical samples of 16 patients with ovarian cancer and 27 patients with ovarian benign cysts were obtained intraoperatively. HOSE were collected by scraping the surface of normal ovaries of 10 post menopausal women undergoing hysterectomy and oophorectomy. Semiquantitative immunohistochemistry was used to assess the presence, distribution, and levels of OGF and OGFr. Receptor binding assays measured binding capacity and affinity of OGFr for radiolabeled OGF. Results: OGF and OGFr were present in HOSE cells, ovarian cysts, and ovarian cancers. Compared to HOSE cells, OGF and OGFr protein levels were reduced 29% and 34% (p < 0.001), respectively, in ovarian cysts, and decreased 58% and 48% (p < 0.001), respectively, in ovarian cancers. Binding assays revealed 5.4 fold fewer OGFr binding sites in cancers than cysts (p < 0.05). Levels of OGF and OGFr were comparable in primary, metastatic, or recurrent ovarian cancers. Conclusion: We have shown that a native opioid pathway, the OGF-OGFr axis, is present in human ovarian cancer. Importantly, the expression of OGF and OGFr is diminished in human ovarian cancer. As OGF and OGFr normally function in maintaining cell proliferation, therapy to harness OGF/OGFr function could provide a useful biologic-based treatment for human ovarian cancer.

AB - Objective: The opioid growth factor (OGF) and its receptor (OGFr), serve as inhibitory axis regulating cell proliferation in normal cells and cancer. We investigated the presence and relative expression of OGF and OGFr in normal human ovarian surface epithelial (HOSE) cells, benign ovarian cysts, and ovarian cancers. Methods: Surgical samples of 16 patients with ovarian cancer and 27 patients with ovarian benign cysts were obtained intraoperatively. HOSE were collected by scraping the surface of normal ovaries of 10 post menopausal women undergoing hysterectomy and oophorectomy. Semiquantitative immunohistochemistry was used to assess the presence, distribution, and levels of OGF and OGFr. Receptor binding assays measured binding capacity and affinity of OGFr for radiolabeled OGF. Results: OGF and OGFr were present in HOSE cells, ovarian cysts, and ovarian cancers. Compared to HOSE cells, OGF and OGFr protein levels were reduced 29% and 34% (p < 0.001), respectively, in ovarian cysts, and decreased 58% and 48% (p < 0.001), respectively, in ovarian cancers. Binding assays revealed 5.4 fold fewer OGFr binding sites in cancers than cysts (p < 0.05). Levels of OGF and OGFr were comparable in primary, metastatic, or recurrent ovarian cancers. Conclusion: We have shown that a native opioid pathway, the OGF-OGFr axis, is present in human ovarian cancer. Importantly, the expression of OGF and OGFr is diminished in human ovarian cancer. As OGF and OGFr normally function in maintaining cell proliferation, therapy to harness OGF/OGFr function could provide a useful biologic-based treatment for human ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=84856018368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856018368&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2011.10.024

DO - 10.1016/j.ygyno.2011.10.024

M3 - Article

C2 - 22037317

AN - SCOPUS:84856018368

VL - 124

SP - 319

EP - 324

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -